Grading of IDH-mutant astrocytoma using diffusion, susceptibility and perfusion-weighted imaging

Xiefeng Yang1, Zhen Xing1, Dejun She1, Yu Lin1, Hua Zhang1, Yan Su1 and Dairong Cao1,2,3*

Abstract

Background: The accurate grading of IDH-mutant astrocytoma is essential to make therapeutic strategies and assess the prognosis of patients. The purpose of this study was to investigate the usefulness of DWI, SWI and DSC-PWI in grading IDH-mutant astrocytoma.

Methods: One hundred and seven patients with IDH-mutant astrocytoma who underwent DWI, SWI and DSC-PWI were retrospectively reviewed. Minimum apparent diffusion coefficient (ADCmin), intratumoral susceptibility signal intensity (ITSS) and maximum relative cerebral blood volume (rCBVmax) values were assessed. ADCmin, ITSS and rCBVmax values were compared between grade 2 vs. grade 3, grade 3 vs. grade 4 and grade 2 vs. grade 4 tumors. Logistic regression, tenfold cross-validation, and receiver operating characteristic (ROC) curve analyses were used to assess their diagnostic performances.

Results: Grade 4 IDH-mutant astrocytomas showed significantly lower ADCmin and higher rCBVmax as compared to grade 3 tumors (adjusted \( P < 0.001 \)). IDH-mutant grade 3 astrocytomas showed significantly lower ITSS levels as compared with grade 4 tumors (adjusted \( P < 0.001 \)). ITSS levels between IDH-mutant grade 2 and grade 3 astrocytomas were significantly different (adjusted \( P = 0.002 \)). Combined the ADCmin, ITSS and rCBVmax resulted in the highest AUC for differentiation grade 2 and grade 3 tumors from grade 4 tumors.

Conclusion: ADCmin, rCBVmax and ITSS can be used for grading the IDH-mutant astrocytomas. The combination of ADCmin, ITSS and rCBVmax could improve the diagnostic performance in grading of IDH-mutant astrocytoma.

Keywords: IDH-mutant, Astrocytoma, SWI, DSC-PWI

Background

According to the 2021 World Health Organization (WHO) central nervous system (CNS) classification system, IDH-mutant astrocytomas were divided into three categories: grade 2, IDH-mutant astrocytoma, grade 3, IDH-mutant astrocytoma and grade 4, IDH-mutant astrocytoma [1]. Previous studies revealed that prognosis of IDH-mutant astrocytomas significantly varied according to their grade [2, 3]. The prognosis of grade 4, IDH-mutant astrocytoma, compared with its lower grade counterparts, showed a dismal outcome. Thus, a preoperative grading of these entities could be helpful in patients’ therapeutics and prognostics, especially in patients with contraindication to operation or in cases with unresectable lesions [4].

Diffusion-weighted imaging (DWI) could noninvasively assess the Brownian movement of water molecules in vivo, and indirectly reflect the cellularity of cerebral...
tumors by means of apparent diffusion coefficient (ADC) values [5]. Dynamic susceptibility contrast perfusion-weighted imaging (DSC-PWI) could provide hemodynamic parameters with tumor angiogenesis and may be useful for glioma grading [6]. As another advanced technique, susceptibility-weighted imaging (SWI) can semi-quantitatively assess tumor micro-hemorrhages and vasculature through intratumoral susceptibility signal intensity (ITSS) [7]. All these methods have been reported differentiation between various grades of gliomas [8–11]. However, few studies focus on grading of IDH-mutant astrocytic gliomas. Therefore, we determined to focus on our study about IDH-mutant astrocytic gliomas only, according to the updated WHO classification. We hypothesized that advanced imaging techniques including DWI, SWI, and DSC-PWI might be useful for grading of IDH-mutant astrocytic gliomas, and the combination of DWI, DSC-PWI, and SWI may contribute to improve the accuracy of diagnosis in IDH-mutant astrocytic gliomas.

**Methods**

**Patients**

This retrospective study was approved by the ethics committee of our hospital and patients’ informed consent was waived. Patients from July 2014 to March 2020 were reviewed at our hospital. The inclusion criteria were the following: (1) IDH-mutant grade 2–4 astrocytomas confirmed by histopathology according to the 2021 WHO classification criteria; (2) a pretreatment MRI scans included conventional MRI(cMRI), DWI, SWI and DSC-PWI. The exclusion criteria were as follows: (1) motion artifacts; (2) poor images quality. A total of 107 patients, including 56 patients with grade 2 IDH mutant astrocytoma, 29 patients with grade 3 IDH mutant astrocytoma, and 22 patients with grade 4 IDH mutant astrocytoma, were enrolled in this study. Of these patients, 63 were male and 44 were female. The age of patients ranged from 18 to 68 years, with a mean age of 40.39 years.

**MRI Protocol**

Imaging was performed with 3.0 T MR systems (Magnetom Skyra or Verio; Siemens, Erlangen, Germany). The cMRI sequences included T2WI, FLAIR, T1WI, and contrast-enhanced T1WI. All cMRI sequences were performed with a field of view (FOV) = 220 mm × 220 mm, slices = 20, slice thickness = 5 mm and interslice gap = 1 mm. The total scan time of T2WI, FLAIR, T1WI, and contrast-enhanced T1WI were 72 s, 66 s, 136 s, and 66 s, respectively. DWI was performed with a single-shot echo planar imaging sequence. The b-values were 0 and 1000 s/mm² with diffusion gradients encoded in the 3 orthogonal directions to generate 3 sets of diffusion-weighted images. The ADC map was generated automatically by the MR imaging system. The imaging parameters were as follows: FOV = 220 mm × 220 mm, repetition time/echo time (TR/TE) = 8200/102 ms; NEX = 2.0; slices = 20; slice thickness = 5 mm; interslice gap = 1 mm. The total scan time was 1 min 32 s.

SWI was performed by 3D fully flow-compensated gradient echo sequence, and a reconstruction by combining the magnitude and phase images. SWI map was generated automatically on the MR imaging scanner. The parameters were as follows: FOV = 220 mm × 220 mm; TR/TE = 27/20 ms; flip angle (FA) = 15°; NEX = 1; slices = 60; slice thickness = 2.0 mm; intersection gap = 0.4 mm. The total scan time was 2 min 19 s.

DSC-PWI was obtained with a gradient-recalled T2*-weighted echo-planar imaging sequence. The imaging parameters were as follows: FOV = 220 mm × 220 mm; TR/TE = 1000–1250/54 ms; FA = 35°; NEX = 1.0; slices = 20; slice thickness/intersection gap = 5 mm/1 mm. When the scan was to the fourth phase of DSC-PWI, 0.1 mmol/kg body weight of gado-pentetate dimeglumine was injected with an MR-compatible power injector at a flow rate of 5 ml/s through an intravenous catheter, followed by a 20 ml continuous saline flush. The series of 20 sections, 60 phases, and 1200 images were acquired in 1 min 36 s. T2* weighted signal was converted to ∆R2* for CBV processing. The whole-brain CBV maps were obtained by using a single-compartment model, T1 extravasation correction, and an arterial input function. The anterior or medial cerebral artery was identified manually for the arterial input function.

**Image analysis**

For the analysis of DWI data, five non-overlapping small round regions of interest (ROIs) were carefully placed in the tumor of the ADC maps to obtained minimum ADC values (ADCₘᵢₙ) with visual inspection [12]. The ROIs (20-40 mm²) were placed in the solid part of the lesion (defined on T2WI, SWI and contrast-enhanced T1WI), avoiding necrotic, cystic, hemorrhagic, or apparent blood vessel regions that might affect the measurements of ADC values.

Minimum intensity projection (MIP) technique was conducted for the semi-quantitative assessment of SWI. ITSS scores were evaluated in consensus by two neuroradiologists (with 13 and 5 years of experience, respectively) who blinded to tumor histopathology. The degree of ITSSs contained four grades as previously described [7]: (1) grade 0 = no ITSS; (2) grade 1 = 1–5 dot-like or
linear ITSSs; (3) grade 2 = 6–10 dot-like or linear ITSSs; and (4) grade 3 ≥ 11 dot-like or linear ITSSs.

For the evaluation of DSC-PWI data, five non-overlapping round ROIs were placed in the tumor on the CBV map to obtained maximum CBV (CBV\text{max}). When the rCBV ROIs were drawn, an attempt was made to place them in regions where the rCBV appeared highest. To minimize variances, the relative CBV\text{max} (rCBV\text{max}) was measured by dividing the tumor CBV\text{max} by the mean CBV of the contralateral normal appearing white matter. Measurements of rCBV\text{max} values were performed with the same ROIs as those used for ADC measurements. The ROIs for the ADC and rCBV measurements were not identical and were not from the same region of the tumor in each patient. ADC\text{min} and rCBV\text{max} values were obtained by another neuroradiologist (with 7 years of experience) who blinded to tumors histopathologic data.

**Statistical analysis**

Initially, Kolmogorov–smirnov test was used for normality of ADC\text{min} and rCBV values. Kruskall-Wallis one way analysis of variance (ANOVA) was used to seek the difference of ADC\text{min} and rCBV\text{max} values between the three grades of the tumor. Comparisons of ADC\text{min} and rCBV values among different grade IDH-mutant astrocytomas were made with student’s t-test. Interobserver variabilities of ITSSs levels were analyzed by kappa statistics. Fisher’s exact test was used to assess ITSS scores among different grade IDH-mutant astrocytomas. Bonferroni correction was performed for multiple comparisons of ADC\text{min}, ITSS, and rCBV, and the corrected p values should be less than 0.0125.

A simple linear regression analysis was performed to calculate the Spearman’s correlation coefficient between ADC\text{min}, ITSS, rCBV\text{max} and tumor grades.

Logistic regression analysis was used to assess the diagnostic effect of total parameters from the DWI, SWI and DSC-PWI model. The receiver operating characteristic (ROC) analysis curves with tenfold cross-validation were obtained to determine the optimal cutoff value for differentiating grade 2, 3 and 4 IDH-mutant astrocytoma. For each logistic regression model, cross-validation was performed with a tenfold procedure. The optimal cutoff value was determined as the point in the upper left-hand corner that maximized the sum of the sensitivity and specificity. In addition, comparisons of area under the ROC curve (AUC) for different quantitative variables were made with Z test proposed by DeLong et al. [13].

Statistical analysis was conducted by Statistical Package for the Social Sciences (version 19.0.0, Inc., Chicago, IL, USA), R, Version R 4.1.2 (R Project for Statistical Computing, http://www.r-project.org), and MedCalc (version 12.1.0. Inc., Mariakerke, Belgium). P value less than 0.05 was statistically significant.

**Results**

The interobserver agreement of ITSS was excellent (Kappa coefficients = 0.858). The ADC\text{min}, ITSS and rCBV\text{max} values of tumors with various grades were summarized in Table 1–2 and Fig. 1. Figures 2, 3 and 4 showed the cases of IDH-mutant astrocytomas with different grades. ADC\text{min} and rCBV\text{max} values were significant different between grade 2 + 3 and grade 4 IDH-mutant astrocytomas, and between grade 3 and grade 4 IDH-mutant astrocytomas (both adjusted P < 0.001). while ITSS scores were significant different between grade 2 and grade 3 IDH-mutant astrocytomas, and between grade 2 + 3 and grade 4 IDH-mutant astrocytomas (adjusted P = 0.002, < 0.001, respectively).

**Spearman’s analysis**

Spearman’s test demonstrated significant relationships between the ITSS scores and the grades of tumor (r = 0.615, P < 0.001). Both ADC\text{min} and rCBV\text{max} have significant correlations with grades of IDH-mutant astrocytomas.

**Table 1** Summary of ADC\text{min}, ITSS and rCBV values among three grades of IDH-mutant astrocytomas

|                  | Grade 2 | Grade 3 | Grade 4 | Grade 2 vs 3 | Grade 3 vs 4 | Grade 2 vs 4 |
|------------------|---------|---------|---------|--------------|--------------|--------------|
| ADC\text{min}    | 1.17 ± 0.20 | 1.06 ± 0.21 | 0.74 ± 0.13 | 0.055 | < 0.001 | < 0.001 |
| ITSS             | 0.43 ± 0.81 | 1.34 ± 1.40 | 2.55 ± 0.80 | 0.002 | < 0.001 | < 0.001 |
| rCBV\text{max}   | 1.67 ± 0.85 | 2.11 ± 1.14 | 5.92 ± 2.26 | 0.506 | < 0.001 | < 0.001 |

ADC\text{min}, Minimum apparent diffusion coefficient, ITSS Intratumoral susceptibility signal, rCBV\text{max}, Relative maximum cerebral blood volume, AUC Area under the curve. CI, confidence interval.
astrocytomas (rCBV\(_\text{max}\), \(r = 0.662\) and \(P < 0.001\); ADC\(_\text{min}\), \(r = 0.638\) and \(P < 0.001\)).

**ROC curve analysis**

The results of ROC curve analysis are shown in Table 3–4 and Fig. 5. The AUCs of rCBV\(_\text{max}\) values in differentiating different grades of IDH mutant astrocytomas from grade 2 to grade 3, grade 3 to grade 4, grade 2 to grade 4 and grade 2+3 to grade 4 were 0.610, 0.955, 0.959 and 0.957, respectively. The AUCs of ADC\(_\text{min}\) in differentiating different grades of IDH mutant astrocytomas from grade 2 to grade 3, grade 3 to grade 4, grade 2 to grade 4 and grade 2+3 to grade 4 were 0.705, 0.907, 0.989 and 0.958, respectively. The AUCs of ITSS in differentiating different grades of IDH mutant astrocytomas from grade 2 to grade 3, grade 3 to grade 4, grade 2 to grade 4 and grade 2+3 to grade 4 were 0.683, 0.827, 0.946 and 0.903, respectively. ITSS > 1 was used to differentiate IDH-mutant astrocytomas grade 3 from grade 2 with sensitivity and specificity of 41% and 91%, respectively. The sensitivity and specificity of ITSS > 1 in differentiating grade 2 and grade 4 IDH-mutant astrocytomas were 81.8% and 58.6%, respectively. Compared grade 2+3 with grade 4 IDH-mutant astrocytomas, a threshold value of > 1 for ITSS resulted in a sensitivity of 81.8% and specificity of 80.0%. A rCBV cutoff value of 3.84 could differentiate grade 2+3 from grade 4 IDH-mutant astrocytomas with a sensitivity of 94.4% and specificity of 94.2%. Combination of rCBV\(_\text{max}\), ADC\(_\text{min}\) and ITSS did not improve classification of grade 2 from grade 3 IDH-mutant astrocytomas. A significant difference was found on the AUC between ITSS and ADC\(_\text{min}\) + ITSS + rCBV\(_\text{max}\) (\(Z = 2.468, P = 0.014\)).

**Discussion**

In the current study, we demonstrated the usefulness of ADC\(_\text{min}\), ITSS and rCBV\(_\text{max}\) values for grading IDH-mutant astrocytomas. The combination of ADC\(_\text{min}\), ITSS and rCBV\(_\text{max}\) values showed a better trend to distinguish the grade 2 and/or grade 3 IDH-mutant astrocytomas from grade 4 IDH-mutant astrocytomas.

The diffusion of water molecules could be limited by tumor cells and subcellular structures. DWI could noninvasively reflect the restricted diffusion of water molecules and evaluate tumor cellularity by ADC values [5]. Previous studies revealed that the ADC values decreased significantly in high-grade astrocytic tumors [14]. Our findings showed a significant difference of ADC values between grade 2+3 and grade 4, which were consistent with previous studies. In addition, our study demonstrated that the ADC\(_\text{min}\) value of grade 4 IDH-mutant astrocytomas was comparable with study by Tan et al. [15]. Prior studies reported the differences of ADC values among grade 2, 3 and 4 astrocytoma without considering IDH mutational status [16]. However, the current study assessed the values of ADC\(_\text{min}\) in different grades of IDH-mutant astrocytomas. Moreover, we also evaluated the difference of grade 2+3 and grade 4 IDH-mutant astrocytomas since some researchers have reported similar prognosis between grade 2 and grade 3 IDH-mutant astrocytomas [17–19]. Consequently, we found significant difference of ADC\(_\text{min}\) values between grade2+3 and grade 4 tumors, but no significant difference of ADC\(_\text{min}\) was observed between grade 2 and grade 3 tumors. It has been reported that high ADC value was correlated with favorable prognosis [20], our results will be conducive...
to the prognosis evaluation of patients with IDH-mutant astrocytomas based on ADC measurement. DSC-PWI could provide the vascularity and angiogenesis information of astrocytoma by rCBV values [21]. Higher grade gliomas tend to have higher rCBV values [6, 22, 23]. Several studies have reported that rCBV was useful in grading astrocytomas [24–26]. Saini et al. [10] found that CBV could be used to differentiate the grade II gliomas and grade III gliomas with high sensitivity and specificity. In contrast, our study found no significant difference of rCBV\textsubscript{max} between grade 2 and grade 3. This discrepancy may be due to the enrolled patients were different and previous investigations did not consider the IDH mutational status of gliomas. It has been shown that IDH mutation leads to 2-HG accumulation, which may decreased hypoxia-inducible-factor-1 activation and inhibited angiogenesis-related signaling [27, 28]. Some previous studies reported that rCBV values were significantly correlated with time to progression in patients with gliomas [20, 29, 30]. This may also be used to explain why grade 2 and grade 3 IDH-mutant astrocytomas have few difference in survival. We found that the rCBV\textsubscript{max} values of grade 2 and grade 3 were lower than those of grade 4,
which may be ascribed to elevate vascular proliferation in high-grade tumors.

Previous studies have demonstrated that SWI was useful for grading astrocytomas [9, 10]. In our study, most of patients with grade 4 IDH-mutant astrocytomas demonstrated an ITSS score of 3 and majority of patients with grade 2 showed no ITSS. Astrocytomas contained high levels of deoxyhemoglobin, due to angiogenesis and the increase of blood supply [24]. Additionally, deoxyhemoglobin generates susceptibility effect, which is related to the signal loss on SWI. The present study showed that ITSS was not detected in 13 of 29 patients with grade 3 IDH-mutant astrocytomas. However, Saini et al. [10] reported that all of the anaplastic astrocytomas could be seen with ITSS. A possible reason was the relatively small sample of anaplastic astrocytoma in their study. Our findings revealed that ITSS scores were significant difference between grade 2+3 and grade 4 IDH-mutant astrocytomas, suggesting that ITSS may serve as a potential biomarker for grading IDH-mutant astrocytic gliomas. In the current study, ITSS socres were significant different between grade 2 and grade 3 IDH-mutant
Fig. 4 A 43-year-old man with grade 4 IDH-mutant astrocytoma. a. ADC map shows a decreased ADC value in the lesion ($ADC_{\text{min}} = 0.916 \times 10^{-3}\text{mm}^2/\text{s}$). b. SWI shows medium susceptibility signal. c. Post-contrast T1WI shows markedly nodular contrast enhancement. d. rCBV map demonstrates relatively high perfusion with the rCBV value of 4.68.

Table 3 Summary of ROC curve results to distinguish various grades of IDH-mutant astrocytoma

|                          | Grade 2 vs 3 (AUC, 95%CI) | Grade 3 vs 4 (AUC, 95%CI) | Grade 2 vs 4 (AUC, 95%CI) | Grade 2 + 3 vs 4 (AUC, 95%CI) |
|--------------------------|---------------------------|---------------------------|---------------------------|-----------------------------|
| $ADC_{\text{min}}$       | 0.701(0.535–0.859)        | 0.898(0.804–0.991)        | 0.985(0.962–1.000)        | 0.956(0.906–0.993)           |
| ITSS                     | 0.678(0.537–0.816)        | 0.820(0.689–0.954)        | 0.943(0.885–1.000)        | 0.900(0.821–0.975)           |
| $rCBV_{\text{max}}$      | 0.602(0.456–0.758)        | 0.950(0.881–0.995)        | 0.953(0.898–1.000)        | 0.954(0.904–0.995)           |
| $ADC_{\text{min}} + ITSS$| 0.737(0.603–0.854)        | 0.921(0.788–0.983)        | 0.992(0.918–1.000)        | 0.967(0.935–1.000)           |
| $ADC_{\text{min}} + rCBV_{\text{max}}$ | 0.695(0.558–0.811) | 0.985(0.962–1.000) | 0.991(0.933–1.000) | 0.973(0.964–1.000) |
| ITSS + $rCBV_{\text{max}}$ | 0.704(0.545–0.841)       | 0.958(0.840–0.996)        | 0.960(0.946–1.000)        | 0.958(0.932–1.000)           |
| $ADC_{\text{min}} + ITSS + rCBV_{\text{max}}$ | 0.746(0.611–0.853)      | 0.987(0.886–1.000)        | 0.998(0.983–1.000)        | 0.994(0.983–1.000)           |

AUC Area under the curve, CI Confidence interval
astrocytomas while rCBV_{max} were not. We speculated that ITSS reflected not only blood vessels but also micro-bleeding and necrosis of tumor, which may lead to the above results.

We found a positive correlation between rCBV_{max} and tumor grade, which is consistent with previous study [9]. Our study found that ITSS was correlated with tumor grade; this finding was in accordance with the results from previous studies [9, 31]. Our results showed that there was a negative correlation between ADC_{min} and tumor grade, suggesting that tumor grade is closely related to the proliferation of tumor cells [32].

We found that the area under ROC for combined ADC_{min}, rCBV_{max} and ITSS was significantly larger than ITSS used alone for grade 3 and grade 4 IDH-mutant astrocytomas. For grade 2+3 and grade 4 IDH-mutant astrocytomas, AUC for combined DWI, SWI and DSC-PWI1 was larger than DWI, SWIand DSC-PW1alone. Our results suggested that the combination of those advanced MRI techniques could improve the diagnostic efficacy in grading IDH-mutant astrocytic gliomas.

This study has some limitations. The retrospective design and single-center sampling may lead to selection bias. Wetzel et al. [33] assessed inter- and intraobserver reproducibility for different techniques of measuring rCBV in patients with intracranial mass lesions, and they found the method that we used to obtain rCBV provides a high interobserver and intraobserver reproducibility. For this retrospective analysis, the DSC-PWI acquisition in our study is suboptimal and was not obtained according to the national consensus recommendation [34]. A multi-centered prospective investigation with standard

Table 4  Threshold values, sensitivity, specificity, PPV and NPV for distinguishing grade 2+3 IDH-mutant astrocytoma from grade 4 IDH-mutant astrocytoma

| Cut-off | Sensitivity(%) | Specificity(%) | PPV(%) | NPV(%) |
|---------|----------------|----------------|--------|--------|
| ADC_{min} | 0.94 | 100.00 | 85.01 | 66.70 | 96.00 |
| ITSS | 1 | 81.80 | 80.00 | 51.40 | 94.40 |
| rCBV_{max} | 3.84 | 94.44 | 94.64 | 85.00 | 98.10 |
| ADC_{min} + ITSS | 94.44 | 91.07 | 77.30 | 98.10 |
| ADC_{min} + rCBV_{max} | 100.00 | 89.29 | 75.00 | 100.00 |
| ITSS + rCBV_{max} | 100.00 | 85.71 | 69.20 | 100.00 |
| ADC_{max} + ITSS + rCBV_{max} | 100.00 | 92.86 | 81.80 | 100.00 |

PPV Positive predictive value, NPV Negative predictive value

Fig. 5  Comparison of receiver operating characteristic curves of ADC, ITSS and rCBV a and ADC + ITSS, ADC + rCBV, rCBV + ITSS and ADC + ITSS + rCBV b in differentiating grade 2+3 from grade 4 IDH-mutant astrocytomas
DSC-PWI acquisition is warranted to verify these results and ensure the reproducibility. Additionally, other genetic alterations such as CDKN2A/B and CDK4 were not assessed because of relevant molecular informations were not available in our study. Advanced MRI imaging techniques combined with larger datasets on other genetic alterations should be performed in future studies.

**Conclusions**

DWI, SWI and DSC-PWI are useful for assessing the tumor grade in this cohort of patients with IDH-mutant astrocytomas. A combination of ADC_{min}, ITSS and rCBV_{max} may improve the diagnostic accuracy of IDH-mutant astrocytomas grading.

**Abbreviations**

MRI: Magnetic resonance imaging; CBV: Cerebral blood volume; rCBV_{max}: Relative maximum cerebral blood volume; ADC_{min}: Minimum apparent diffusion coefficients; DWI: Diffusion weighted imaging; SWI: Susceptibility-weighted imaging; ITSS: Intratumoral susceptibility signal intensity; ADC: Apparent diffusion coefficients; DSC-PWI: Dynamic susceptibility contrast perfusion-weighted imaging; FOV: Field of view; ROI: Region of interest.

**Acknowledgements**

Not applicable.

**Author contributions**

XY and DC designed this study; XY wrote the main manuscript; YL and ZX revised the manuscript. DS and HZ did the statistical analysis. YS prepared all figures. All authors read and approved the final manuscript.

**Funding**

This work was funded by the Startup Fund for Scientific Research, Fujian Medical University (No. 2018QH1075), the Fujian Provincial Health Technology Project (No.2021QN8006), the Funding Project of Medical Innovation of Fujian Province (No. 2019-CX-23), the Joint Project of Health and Education of Fujian Province (No. 2019-WJ-10), the Leading Project of the Department of Science and Technology of Fujian Province(NO.2020Y0023), and the National Natural Science Foundation of China (No. 82071869).

**Availability of data and materials**

Due to statutory provisions regarding data and privacy protection, the dataset supporting the conclusions of this article is available upon individual request directed to the corresponding author.

**Declarations**

**Ethics approval and consent to participate**

This study was approved by the Ethics Committee of the First Affiliated Hospital of Fujian Medical University, and the informed consent was waived due to the nature of the retrospective study. All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Department of Radiology, First Affiliated Hospital of Fujian Medical University, 20 Cha-Zhong Road, Fuzhou 350005, Fujian, People’s Republic of China.
2. Fujian Key Laboratory of Precision Medicine for Cancer, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, People’s Republic of China.
3. Key Laboratory of Radiation Biology of Fujian Higher Education Institutions, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, People’s Republic of China.

**Received**: 22 November 2021 **Accepted**: 24 May 2022

**Published online**: 29 May 2022

**References**

1. Louis D, Perry A, Wesseling P, The, et al. WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;2021:23.
2. Shirahata M, Ono T, Chisel D, et al. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathol. 2018;136:153–66.
3. Juchi T, Sugiyama T, Ohira M, et al. Clinical significance of the 2016 WHO classification in Japanese patients with gliomas: Brain Tumor Pathol. 2018;35:71–80.
4. Weller M, Den Bent MJ, Tonn JC, et al. European association for neuro-oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017;18:815–29.
5. Le Bihan D. Looking into the functional architecture of the brain with diffusion MRI. Nat Rev Neurosci. 2003;4:469–80.
6. Shin JH, Lee HK, Kwon BD, et al. Using relative cerebral blood flow and volume to evaluate the histopathologic grade of cerebral gliomas: preliminary results. Am J Roentgenol. 2002;179:783–9.
7. Park MJ, Kim HS, Jahng GH, Ryu CW, Park SM, Kim SY. Semiquantitative assessment of intratumoral susceptibility signals using non-contrast-enhanced high-field high-resolution susceptibility-weighted imaging in patients with gliomas: comparison with MR perfusion imaging. Am J Neuroradiol. 2009;30:1402–8.
8. Lee K, Ott GA, Lai A, et al. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas. J Neurooncol. 2017;134:177–88.
9. Wang XC, Zhang H, Tan Y, et al. Combined value of susceptibility-weighted and perfusion-weighted imaging in assessing who grade for brain astrocytomas. J Mag Reson Imag JMRI. 2014;39:1569–74.
10. Sani J, Gupta PK, Sahoo P, et al. Differentiation of grade II and grade IV glioma by combining “T1 contrast-enhanced brain perfusion imaging” and susceptibility-weighted quantitative imaging. Neuroradiology. 2018;60:43–50.
11. Bhattacharjee R, Gupta RK, Patir R, Vaishya S, Ahlawat S, Singh A. Quantitative vs semiquantitative assessment of intratumoral susceptibility signals in patients with different grades of gliomas. J Mag Reson Imag JMRI. 2020;51:225–33.
12. Boxerman JL, Shiroishi MS, Bリングton BM, Pope WB. Dynamic susceptibility contrast MR imaging in glioma. Magn Reson Imaging Clin N Am. 2016;24:649–70.
13. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a non-parametric approach. Biometrics. 1988;44:837–45.
14. Higano S, Yun X, Kubake T, et al. Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology. 2006;241:839–46.
15. Tan WL, Huang YJ, Yim B, Xiong J, Wu JS, Geng D. Can diffusion tensor imaging noninvasively detect IDH1 gene mutations in astrogliaomas? A retrospective study of 112 cases. Am J Neuroradiol. 2014;35:920–7.
16. Qin JB, Zhang H, Wang XC, Tan Y, Wu X. Combination value of diffusion-weighted imaging and dynamic susceptibility contrast-enhanced MRI in astrocytoma grading and correlation with GFAP Tposomserase Ila and NGFM Oncol Lett. 2019;18:2763–70.
17. Brat DJ, Verhaak RG, Aldape KD, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372:2481–98.
18. Olar A, Wani KM, Fararo-Munoz KD, et al. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathol. 2015;129:585–96.
19. Reuss DE, Marnatayan T, Schmimpf D, et al. IDH mutant diffuse and anaplastic astrocytomas: have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol. 2015;129:867–73.
20. Zulfiqar M, Yousem DM, Lai H. ADC values and prognosis of malignant astrocytomas: does lower ADC predict a worse prognosis independent of grade of tumor? – a meta-analysis. AJR Am J Roentgenol. 2013;200:624–9.
21. Caseiras GB, Chheang S, Babb J, et al. Relative cerebral blood volume measurements of low-grade gliomas predict patient outcome in a multi-institution setting. Eur J Radiol. 2010;73:215–20.
22. Jain R, Gutierrez JA, Narang J, et al. In vivo correlation of tumor blood volume and permeability with histologic and molecular angiogenic markers in gliomas. Am J Neuroradiol. 2011;32:388–94.
23. Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. Am J Neuroradiol. 2003;24:1989–98.
24. Wang X, Zhang H, Tan Y, et al. Combined value of susceptibility-weighted and perfusion-weighted imaging in assessing WHO grade for brain astrocytomas. J Magn Reson Imaging. 2014;39:1569–74.
25. Hilario A, Ramos A, Perez-Ruiz N, et al. The added value of apparent diffusion coefficient to cerebral blood volume in the preoperative grading of diffuse gliomas. Am J Neuroradiol. 2012;33:701–7.
26. Lupo JM, Cha S, Chang SM, Nelson SJ. Analysis of metabolic indices in regions of abnormal perfusion in patients with high-grade glioma. Am J Neuroradiol. 2007;28:1455–61.
27. Loosan J, Loopo RE, Koivunen P, et al. (R)-2-Hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science. 2013;339:1621–5.
28. Koivunen P, Lee S, Duncan CG, et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature. 2012;483:484–8.
29. Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology. 2008;247:490–8.
30. Mangla R, Ginat DT, Kamalian S, et al. Correlation between progression free survival and dynamic susceptibility contrast MRI perfusion in WHO grade III glioma subtypes. J Neurooncol. 2014;116:325–31.
31. Park MJ, Kim HS, Jahng GH, Ryu CW, Park SM, Kim SJ. Semiquantitative assessment of intratumoral susceptibility signals using non-contrast-enhanced high-field high-resolution susceptibility-weighted imaging in patients with gliomas: comparison with MR perfusion imaging. AJNR Am J Neuroradiol. 2009;30:1402–8.
32. Kang XW, Xi YB, Liu TT, et al. Grading of Glioma: combined diagnostic value of amide proton transfer weighted, arterial spin labeling and diffusion weighted magnetic resonance imaging. BMC Med Imaging. 2020;20:50.
33. Wetzel SG, Cha S, Johnson G, et al. Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology. 2002;224:797–803.
34. Boxerman JL, Quarles CC, Hu LS, et al. Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas. Neuro Oncol. 2020;22:1262–75.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- Fast, convenient online submission
- Thorough peer review by experienced researchers in your field
- Rapid publication on acceptance
- Support for research data, including large and complex data types
- Gold Open Access which fosters wider collaboration and increased citations
- Maximum visibility for your research: over 100M website views per year

Learn more: biomedcentral.com/submissions